206 related articles for article (PubMed ID: 37967403)
21. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
22. Risk of lymphoma in inflammatory bowel disease.
Loftus EV; Tremaine WJ; Habermann TM; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2000 Sep; 95(9):2308-12. PubMed ID: 11007233
[TBL] [Abstract][Full Text] [Related]
23. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Hanauer SB; Stathopoulos G
Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
25. Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.
Greuter T; Porchet F; Braga-Neto MB; Rossel JB; Biedermann L; Schreiner P; Scharl M; Schoepfer AM; Safroneeva E; Straumann A; Rogler G; Vavricka SR
United European Gastroenterol J; 2020 Dec; 8(10):1196-1207. PubMed ID: 33276710
[TBL] [Abstract][Full Text] [Related]
26. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
[TBL] [Abstract][Full Text] [Related]
27. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
28. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L; Rahier JF; Kirchgesner J; Abitbol V; Shaji S; Armuzzi A; Karmiris K; Gisbert JP; Bossuyt P; Helwig U; Burisch J; Yanai H; Doherty GA; Magro F; Molnar T; Löwenberg M; Halfvarson J; Zagorowicz E; Rousseau H; Baumann C; Baert F; Beaugerie L;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):771-788.e10. PubMed ID: 36152897
[TBL] [Abstract][Full Text] [Related]
29. [Compliance to drug therapy in inflammatory bowel diseases outpatients from a university hospital].
Dewulf Nde L; Monteiro RA; Passos AD; Vieira EM; Troncon LE
Arq Gastroenterol; 2007; 44(4):289-96. PubMed ID: 18317646
[TBL] [Abstract][Full Text] [Related]
30. Increasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study.
Olén O; Smedby KE; Erichsen R; Pedersen L; Halfvarson J; Hallqvist-Everhov Å; Bryder N; ; Askling J; Ekbom A; Sachs MC; Sørensen HT; Ludvigsson JF
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3132-3142. PubMed ID: 37061104
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory bowel disease is not associated with an increased risk of lymphoma.
Lewis JD; Bilker WB; Brensinger C; Deren JJ; Vaughn DJ; Strom BL
Gastroenterology; 2001 Nov; 121(5):1080-7. PubMed ID: 11677199
[TBL] [Abstract][Full Text] [Related]
32. Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.
Zhou W; Huang Y; Lai J; Lu J; Feely M; Liu X
Gastroenterology Res; 2018 Jun; 11(3):174-188. PubMed ID: 29915627
[TBL] [Abstract][Full Text] [Related]
33. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Johnson CM; Dassopoulos T
Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
[TBL] [Abstract][Full Text] [Related]
35. Drug therapy of inflammatory bowel disease.
Sack DM; Peppercorn MA
Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
[TBL] [Abstract][Full Text] [Related]
36. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.
Satsangi J; Welsh KI; Bunce M; Julier C; Farrant JM; Bell JI; Jewell DP
Lancet; 1996 May; 347(9010):1212-7. PubMed ID: 8622450
[TBL] [Abstract][Full Text] [Related]
37. Genetics of inflammatory bowel disease.
Satsangi J; Parkes M; Jewell DP; Bell JI
Clin Sci (Lond); 1998 May; 94(5):473-8. PubMed ID: 9682668
[TBL] [Abstract][Full Text] [Related]
38. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
[TBL] [Abstract][Full Text] [Related]
39. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
